Published on 24 Apr 2024 on Insider Monkey via Yahoo Finance
Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P 500 Index. The fund rose 13.61% on an annualized basis since its inception on April 30, 2018, compared to an 11.45% gain for the benchmark and a 14.24% gain for the index. In addition, please check the fund’s top five holdings to know its best picks in 2024.
Baron Health Care Fund featured stocks like Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) in the first quarter 2024 investor letter. Headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a biotechnology company. On April 23, 2024, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock closed at $23.67 per share. One-month return of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) was -12.95%, and its shares gained 35.31% of their value over the last 52 weeks. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) has a market capitalization of $2.149 billion.